LC Ventures

Yuyao Biotech is a biotechnology company dedicated to addressing significant unmet clinical needs through innovative drug development. The firm specializes in creating new therapies for hematological tumors, neurodegenerative diseases, and autoimmune disorders. Utilizing artificial intelligence and advanced drug creation technologies, Yuyao Biotech emphasizes small molecule drug discovery to develop effective treatments for these challenging conditions. By prioritizing innovation, the company aims to enhance human health and improve the quality of life for patients affected by these diseases.

LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.

Haixin zhihui is an artificial intelligence company. They offer intelligent diagnosis, and treatment systems for tumor diseases have been developed. They provide patients with precise treatment recommendations and assist patients in treatment planning and full disease management.

Qinhao Pharmaceutical is a biotechnology firm focusing on developing effective small-molecule anti-tumor medications. Drug therapy is one of the important means to overcome tumors. The executive team of the organization has extensive experience in corporate management, innovative drug research and development, and clinical medical research.

Ractigen Therapeutics is an early-stage pharmaceutical company dedicated to developing first-in-class therapies that selectively restore the expression of therapeutic genes silenced in diseased cells. Founded in 2016 by pioneers in the RNA activation field, the company leverages a groundbreaking discovery from the University of California San Francisco, known as RNA activation (RNAa). Ractigen's innovative approach aims to address diseases stemming from inadequate gene expression, with a focus on central nervous system disorders, tumors, liver diseases, and ophthalmic conditions. The company is building a promising pipeline of candidate medicines to meet significant unmet medical needs.

Personal Oncology is a company dedicated to the diagnosis and treatment of tumors, with a particular emphasis on cancer therapy. It has developed an innovative technology known as FASTPDTX, which is designed for patient-derived tumor xenografts (PDTX). This technology has advanced to the clinical use stage, allowing for more precise targeting of cancerous cells. By leveraging detection technology, Personal Oncology aims to enhance the treatment process for physicians and improve patient outcomes. The company's focus on cutting-edge solutions positions it as a significant player in the oncology field, striving to make strides in cancer treatment and management.

Chineo is a company specializing in the development and provision of immune cell therapies, particularly focusing on CAR-T treatments. The company is dedicated to researching and developing cell therapy products aimed at treating tumors and immune diseases. Chineo's work involves utilizing high-throughput gene sequencing (NGS) alongside CAR-T technologies and other advanced cell therapy methods. This approach enables medical practitioners to enhance the diagnosis and treatment of tumors through innovative therapies such as tumor infiltrating lymphocyte therapy (TIL).

Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases.

Immunophage Biotech, established in 2016, is a Chinese pharmaceutical company dedicated to new drug development. Based in Nanjing, with its R&D center in Shanghai's Pujiang High-Tech Park, the company focuses on creating first-in-class immune-regulating therapies for cancer, autoimmune diseases, and neurodegenerative disorders.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Ranok Therapeutics is a biotechnology company developing a novel targeted protein degradation (TPD) technology. This platform aids in discovering and developing new therapeutics, focusing on cancer and other diseases with significant unmet medical needs. Ranok's pipeline includes both validated and novel drug targets, aiming to create safer and more effective therapies.

Righton is a Shanghai-based biotechnology company specializing in genetic engineering. It focuses on the research and development of in vitro diagnostic products, including molecular diagnostic reagent kits. The company is involved in various aspects of the biotechnology field, encompassing production, sales, and scientific research, as well as providing testing services. Righton aims to contribute to advancements in molecular diagnostics through its innovative products and services.

Stemirna Therapeutics is a RNA technology based drug development company designed to maximize the potential of RNA science. The company currently has more than a dozen of independently-developed mRNA drug projects, focusing on the fields of mRNA-based personalized cancer vaccines, mRNA vaccines for infectious disease, protein defects diseases, and genetic diseases, providing cure and solutions for cancer and infectious diseases, better serving patients.

Shouyao Holding is a pharmaceutical company focused on researching, developing, and producing small molecule anti-tumor targeted drugs and new diabetes drugs.